SG11202011243XA - Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate - Google Patents
Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugateInfo
- Publication number
- SG11202011243XA SG11202011243XA SG11202011243XA SG11202011243XA SG11202011243XA SG 11202011243X A SG11202011243X A SG 11202011243XA SG 11202011243X A SG11202011243X A SG 11202011243XA SG 11202011243X A SG11202011243X A SG 11202011243XA SG 11202011243X A SG11202011243X A SG 11202011243XA
- Authority
- SG
- Singapore
- Prior art keywords
- her2
- treatment
- drug conjugate
- administering anti
- mutated cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018101211 | 2018-05-28 | ||
JP2018177132 | 2018-09-21 | ||
PCT/JP2019/020886 WO2019230645A1 (en) | 2018-05-28 | 2019-05-27 | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011243XA true SG11202011243XA (en) | 2020-12-30 |
Family
ID=68698185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011243XA SG11202011243XA (en) | 2018-05-28 | 2019-05-27 | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210205466A1 (en) |
EP (1) | EP3804764A4 (en) |
JP (1) | JP7441165B2 (en) |
KR (1) | KR20210014660A (en) |
CN (1) | CN112153989A (en) |
AU (1) | AU2019278628A1 (en) |
BR (1) | BR112020024061A2 (en) |
CA (1) | CA3101906A1 (en) |
IL (1) | IL278988A (en) |
SG (1) | SG11202011243XA (en) |
TW (1) | TW202015738A (en) |
WO (1) | WO2019230645A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3073383C (en) * | 2017-08-23 | 2023-10-31 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
CN111088353A (en) * | 2019-12-27 | 2020-05-01 | 浙江大学 | Application of pertuzumab drug resistance mutation, detection kit and detection method |
AU2021312537A1 (en) | 2020-07-20 | 2023-03-09 | Daiichi Sankyo Company, Limited | Combination of (anti-HER2 antibody)-drug conjugate and her dimerization inhibitor |
CN116286659A (en) * | 2021-10-25 | 2023-06-23 | 黄�俊 | Application of multimer in detection of CAR expression cells and preparation of cells |
CN116930497B (en) * | 2023-06-27 | 2024-02-06 | 广东省第二人民医院(广东省卫生应急医院) | Kit for detecting exosome HER2 membrane protein and mRNA, application thereof and detection method |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
ATE458007T1 (en) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODIES-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
KR100797308B1 (en) | 1999-06-25 | 2008-01-23 | 제넨테크, 인크. | Humanized Anti-ErbB2 Antibodies and Treatment with Anti-ErbB2 Antibodies |
DK2314686T4 (en) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Cells that form antibody complexes |
PL3466976T3 (en) * | 2014-01-31 | 2021-12-20 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
ES2754348T3 (en) | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugate of (anti-HER2 antibody) -pharmaceutical |
KR20180021723A (en) * | 2015-06-29 | 2018-03-05 | 다이이찌 산쿄 가부시키가이샤 | Method for selectively manufacturing antibody-drug conjugate |
CN109789211A (en) | 2016-10-07 | 2019-05-21 | 第一三共株式会社 | Treatment based on the patience cancer that Anti-HER 2-drug conjugates are bestowed |
-
2019
- 2019-05-27 AU AU2019278628A patent/AU2019278628A1/en active Pending
- 2019-05-27 CN CN201980035852.5A patent/CN112153989A/en active Pending
- 2019-05-27 US US17/058,838 patent/US20210205466A1/en active Pending
- 2019-05-27 JP JP2020522178A patent/JP7441165B2/en active Active
- 2019-05-27 EP EP19812523.9A patent/EP3804764A4/en active Pending
- 2019-05-27 SG SG11202011243XA patent/SG11202011243XA/en unknown
- 2019-05-27 KR KR1020207037050A patent/KR20210014660A/en not_active Application Discontinuation
- 2019-05-27 BR BR112020024061-3A patent/BR112020024061A2/en unknown
- 2019-05-27 CA CA3101906A patent/CA3101906A1/en active Pending
- 2019-05-27 WO PCT/JP2019/020886 patent/WO2019230645A1/en active Application Filing
- 2019-05-28 TW TW108118348A patent/TW202015738A/en unknown
-
2020
- 2020-11-25 IL IL278988A patent/IL278988A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7441165B2 (en) | 2024-02-29 |
JPWO2019230645A1 (en) | 2021-07-08 |
AU2019278628A1 (en) | 2021-01-07 |
IL278988A (en) | 2021-01-31 |
EP3804764A1 (en) | 2021-04-14 |
EP3804764A4 (en) | 2022-04-06 |
CN112153989A (en) | 2020-12-29 |
BR112020024061A2 (en) | 2021-02-17 |
WO2019230645A1 (en) | 2019-12-05 |
KR20210014660A (en) | 2021-02-09 |
TW202015738A (en) | 2020-05-01 |
CA3101906A1 (en) | 2019-12-05 |
US20210205466A1 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202112429PA (en) | Dosage of an antibody-drug conjugate | |
SG11202011243XA (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate | |
IL284274A (en) | Antibody-drug conjugate with improved therapeutic window | |
EP3606964A4 (en) | Subcutaneous administration of antibody-drug conjugates for cancer therapy | |
IL260065A (en) | Axl-specific antibody-drug conjugates for cancer treatment | |
SG10201912173RA (en) | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate | |
SG11202100947SA (en) | Treatment of metastatic brain tumor by administration of antibody-drug conjugate | |
MX2019010202A (en) | Glycan-interacting compounds and methods of use. | |
SG11202104923YA (en) | Pharmaceutical combination for treatment of cancer | |
IL277854A (en) | Antibody-drug conjugates and their uses for the treatment of cancer | |
EP3854418A4 (en) | Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate | |
IL257670A (en) | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer | |
IL292886A (en) | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate | |
SG11202011117VA (en) | Treatment of cancer | |
EP3845252A4 (en) | Use of anti-her2 antibody-drug conjugate in treating urothelial carcinoma | |
IL281845A (en) | Combination therapy for the treatment of cancer | |
IL284162A (en) | Combination therapy for the treatment of cancer | |
IL279609A (en) | Bifunctional compositions for the treatment of cancer | |
SG11202108636SA (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
EP4178574A4 (en) | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer | |
IL283742A (en) | Novel approach for treatment of cancer using immunomodulation | |
CL2018000726A1 (en) | Syd985 conjugate treatment of cancer patients resistant to t-dm1 treatment | |
IL274277A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
MX2018000135A (en) | Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor. | |
IL273874A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |